Developer docs
API playgroundTry for free, no card

Search company profiles

Bioprofarma Bagó

Full company profile

uuid000flo4

Namestring
Bioprofarma Bagó
Legal namestring
Laboratorios Bioprofarma Bagó
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Bioprofarma Bagó (legal name: Laboratorios Bioprofarma Bagó S.A.) is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, headquartered at Terrada 1270, Buenos Aires. Founded in 2003, the company develops, manufactures, and commercializes high-complexity prescription medications targeting five therapeutic verticals: hematology (Benzimir), oncology (Anastradex), special treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), urology (a portfolio of ten products including Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and rare diseases (Eibanta, Gaust). Its core technology is specialized pharmaceutical manufacturing for elevated-complexity pathologies, with proprietary formulations across urology-oncology (enzalutamide, abiraterone acetate, apalutamide, bicalutamide), rare-disease therapeutics (icatibanto, miglustat, sulthiame, edaravone), and oncology APIs (anastrozole). The 2026 acquisition of Eriochem added a wholly owned Argentine oncology laboratory in Entre Ríos.

The company operates a B2B/B2C sales-led GTM motion distributing prescription medications through healthcare institutions, hospitals, and pharmacies under ANMAT regulatory oversight in 28 countries spanning Latin America, Asia-Pacific (including Philippines, Georgia, Mongolia, Myanmar, Vietnam, Thailand, Pakistan, Sri Lanka), and EMEA (Iraq, Lebanon). Revenue mechanics are prescription-driven one-time product sales of high-value-added medications, with the PRIORIDAR patient support program providing adherence, follow-up, and lifestyle services to patients and families. The company employs between 51 and 100 staff (described internally as 'over 80 young collaborators') and is privately held under the Grupo Bagó umbrella, alongside the Biogénesis Bagó animal-health subsidiary that has executed complementary acquisitions of Mayors (Argentina, 2022) and Mundo Animal (Brazil, 2025).

Short descriptiontext

Bioprofarma Bagó is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, developing, manufacturing, and commercializing high-complexity prescription medications across hematology, oncology, urology, special treatments, and rare diseases for patients in 28 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBuenos Aires, Argentina
HQ citystring
Buenos Aires
HQ countrystring
Argentina
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, oncology medications, hematology treatments, rare disease drugs, patient support programs
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceutical Products
TypeOne Time License
Description

Sale of high-value-added medications for the treatment of complex diseases including hematological, oncological, urological conditions, special treatments, and rare diseases

bioprofarma-bago.com.ar
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PRIORIDAR
Description

Patient support program providing information, treatment follow-up, and support services for patients and families during treatment.

bioprofarma-bago.com.ar
Core offering1 text field

Bioprofarma Bagó develops, manufactures, and commercializes high-complexity prescription medications for the treatment of hematological, oncological, and urological conditions, special treatments, and rare diseases. The portfolio includes specialty drugs such as Benzimir (hematology), Anastradex (oncology), Hutus and Androstat (prostate cancer), and Eibanta (hereditary angioedema), distributed through healthcare institutions, hospitals, and pharmacies across Latin America, Asia, the Middle East, and Eastern Europe.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bioprofarma Bagó is a pharmaceutical division of the Argentine Bagó group that develops, produces, and commercializes high-complexity medications. The portfolio consists of five therapeutic categories: Hematology (Benzimir), Oncology (Anastradex), Special Treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), Urology (Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and Rare Diseases (Eibanta, Gaust). The company also provides patient support through the PRIORIDAR program. Products target hematological, oncological, urological conditions, special treatments, and rare diseases, with a global presence across Latin America and select international markets including Philippines, Georgia, Myanmar, Vietnam, Thailand, Pakistan, Iraq, and Lebanon.

Product and service20 records
1Benzimir
CategoryHematology Pharmaceuticals
Description

Hematology medication produced by Bioprofarma Bagó for the treatment of hematological conditions.

2Anastradex
CategoryOncology Pharmaceuticals
Description

Oncology medication for cancer treatment produced by Bioprofarma Bagó.

3Actiluzol
CategorySpecial Treatments Pharmaceuticals
Description

Special treatment medication containing riluzole for neurological conditions.

4Hutus
CategoryUrology Pharmaceuticals
Description

Urology medication containing enzalutamide for prostate cancer treatment.

5Eibanta
CategoryRare Disease Pharmaceuticals
Description

Treatment for acute attacks of hereditary angioedema, presented as a pre-filled syringe with 30mg icatibanto and 25G hypodermic needle.

6Antixan
CategorySpecial Treatments Pharmaceuticals
Description

Special treatment containing edaravone for neurological conditions.

7Gaust
CategorySpecial Treatments Pharmaceuticals
Description

Special treatment containing miglustat for rare diseases.

8Kalisma
CategorySpecial Treatments Pharmaceuticals
Description

Special treatment containing sulthiame.

9Ragnerol
CategorySpecial Treatments Pharmaceuticals
Description

Special treatment containing caspofungin for antifungal therapy.

10Androstat
CategoryUrology Pharmaceuticals
Description

Urology medication containing cyproterone acetate for prostate cancer treatment, presented as 50mg x 50 tablets.

11Bidrostat
CategoryUrology Pharmaceuticals
Description

Urology medication containing bicalutamide for prostate cancer.

12CarciVac
CategoryUrology Pharmaceuticals
Description

Urology medication containing Onco BCG (Bacillus Calmette-Guérin) for bladder cancer treatment.

13Flutrax
CategoryUrology Pharmaceuticals
Description

Urology medication containing flutamide for prostate cancer.

14Kestava
CategoryUrology Pharmaceuticals
Description

Urology medication containing abiraterone acetate for prostate cancer.

15Mitotie
CategoryUrology Pharmaceuticals
Description

Urology medication containing mitomycin for cancer treatment.

16Paknira
CategoryUrology Pharmaceuticals
Description

Urology medication containing apalutamide for prostate cancer.

17Sinresor
CategoryUrology Pharmaceuticals
Description

Urology medication containing zoledronic acid.

18UroControl
CategoryUrology Diagnostics
Description

Urology diagnostic product for liquid biopsy in urine testing.

19Urodif Dúo
CategoryUrology Pharmaceuticals
Description

Urology medication combining dutasteride and tamsulosin hydrochloride.

20PRIORIDAR Patient Program
CategoryPatient Support Services
Description

Patient support program providing information, treatment follow-up, and healthy lifestyle guidance for patients and families undergoing treatment with Bioprofarma Bagó medications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Mundo Animal (Brazil)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) in January 2025 to expand into the pet care market in Brazil, complementing the Mayors acquisition and strengthening the group's Latin American pet health positioning.

cronista.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) to expand into the pet care market in Argentina as part of the group's pet health strategy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bioprofarma Bagó acquired 100% of Eriochem, an Argentine laboratory specializing in oncology medications based in Entre Rios. This acquisition enables synergies in research, production, and commercialization aligned with Bioprofarma Bago's high-impact therapeutic strategy, strengthening their oncology portfolio.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global specialty and generics leader with strong LATAM and emerging market presence. Comparable as a large-scale competitor offering both specialty and generic versions of many molecules Bioprofarma distributes.

2Laboratorios Roemmers
TypeDirect peer
Description

Leading Argentine pharmaceutical company with a broad branded specialty and primary care portfolio across Latin America. Comparable as a fellow Argentine pharma with multi-country LATAM distribution and similar therapeutic breadth.

TypeDirect peer
Description

Argentine oncology-focused laboratory recently acquired by Bioprofarma Bagó. Specializes in oncology medications for high-complexity treatments, making it the closest direct comparator on therapeutic focus and geography.

TypeRegional player
Description

Major LATAM specialty/generics player with strong presence in Chile and broader Andean/Pacific Alliance markets where Bioprofarma also competes in oncology and specialty therapeutics.

5Gador
TypeDirect peer
Description

Argentine pharmaceutical company with strong specialty and oncology presence across LATAM. Directly comparable therapeutic categories (oncology, specialty care) and similar regional distribution model.

TypeBroad incumbent
Description

Parent group of Bioprofarma Bagó and one of the largest Argentine pharmaceutical companies. Operates broadly across multiple therapeutic areas including animal health (Biogénesis Bagó); provides the corporate and distribution backbone for Bioprofarma's specialty division.

7Laboratorios Raffo
TypeDirect peer
Description

Argentine specialty pharmaceutical company with branded generics and specialty products across oncology and complex therapies. Comparable as a mid-sized Argentine pharma competing in similar therapeutic niches.

TypeBroad incumbent
Description

Global originator of enzalutamide (Xtandi), directly competing with Bioprofarma's Hutus in prostate cancer. Representative of the multinational originator competition Bioprofarma faces in urology oncology.

TypeDirect peer
Description

Argentine pharmaceutical group (formed by merger of Elea and Phoenix) with branded specialty products across LATAM. Comparable in scale, therapeutic breadth, and Argentine-headquartered specialty pharma positioning.

TypeOthers
Description

Animal-health subsidiary of the same Bagó Group, with 200+ pet health SKUs and top-10 LATAM ranking. Sister company rather than direct competitor; included as ecosystem context for the parent group's broader pharmaceutical platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioprofarma Bagó

Specialty Pharmaceuticalsbioprofarma-bago.com.ar

Bioprofarma Bagó is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, developing, manufacturing, and commercializing high-complexity prescription medications across hematology, oncology, urology, special treatments, and rare diseases for patients in 28 countries.

What Bioprofarma Bagó does

Bioprofarma Bagó (legal name: Laboratorios Bioprofarma Bagó S.A.) is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, headquartered at Terrada 1270, Buenos Aires. Founded in 2003, the company develops, manufactures, and commercializes high-complexity prescription medications targeting five therapeutic verticals: hematology (Benzimir), oncology (Anastradex), special treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), urology (a portfolio of ten products including Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and rare diseases (Eibanta, Gaust). Its core technology is specialized pharmaceutical manufacturing for elevated-complexity pathologies, with proprietary formulations across urology-oncology (enzalutamide, abiraterone acetate, apalutamide, bicalutamide), rare-disease therapeutics (icatibanto, miglustat, sulthiame, edaravone), and oncology APIs (anastrozole). The 2026 acquisition of Eriochem added a wholly owned Argentine oncology laboratory in Entre Ríos.

The company operates a B2B/B2C sales-led GTM motion distributing prescription medications through healthcare institutions, hospitals, and pharmacies under ANMAT regulatory oversight in 28 countries spanning Latin America, Asia-Pacific (including Philippines, Georgia, Mongolia, Myanmar, Vietnam, Thailand, Pakistan, Sri Lanka), and EMEA (Iraq, Lebanon). Revenue mechanics are prescription-driven one-time product sales of high-value-added medications, with the PRIORIDAR patient support program providing adherence, follow-up, and lifestyle services to patients and families. The company employs between 51 and 100 staff (described internally as 'over 80 young collaborators') and is privately held under the Grupo Bagó umbrella, alongside the Biogénesis Bagó animal-health subsidiary that has executed complementary acquisitions of Mayors (Argentina, 2022) and Mundo Animal (Brazil, 2025).

Bioprofarma Bagó firmographics

Firmographics
Name
Bioprofarma Bagó
Legal name
Laboratorios Bioprofarma Bagó
Website
https://bioprofarma-bago.com.ar
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Bioprofarma Bagó is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, developing, manufacturing, and commercializing high-complexity prescription medications across hematology, oncology, urology, special treatments, and rare diseases for patients in 28 countries.
Ownership category
akta.pro rank

Bioprofarma Bagó industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Oncology medications
  • Hematology treatments
  • Rare disease drugs
  • Patient support programs

Where Bioprofarma Bagó is headquartered

Location

Headquarters

HQ city
Buenos Aires
HQ country
Argentina
HQ region
Latin America

Offices2 records

Markets served

Bioprofarma Bagó business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Pharmaceutical Products: Sale of high-value-added medications for the treatment of complex diseases including hematological, oncological, urological conditions, special treatments, and rare diseases

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Bioprofarma Bagó product offering

Product offering

Core offering

Bioprofarma Bagó develops, manufactures, and commercializes high-complexity prescription medications for the treatment of hematological, oncological, and urological conditions, special treatments, and rare diseases. The portfolio includes specialty drugs such as Benzimir (hematology), Anastradex (oncology), Hutus and Androstat (prostate cancer), and Eibanta (hereditary angioedema), distributed through healthcare institutions, hospitals, and pharmacies across Latin America, Asia, the Middle East, and Eastern Europe.

Product overview

Bioprofarma Bagó is a pharmaceutical division of the Argentine Bagó group that develops, produces, and commercializes high-complexity medications. The portfolio consists of five therapeutic categories: Hematology (Benzimir), Oncology (Anastradex), Special Treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), Urology (Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and Rare Diseases (Eibanta, Gaust). The company also provides patient support through the PRIORIDAR program. Products target hematological, oncological, urological conditions, special treatments, and rare diseases, with a global presence across Latin America and select international markets including Philippines, Georgia, Myanmar, Vietnam, Thailand, Pakistan, Iraq, and Lebanon.

Differentiator

Problem solved

Functional benefit

Brands

  • PRIORIDAR: Patient support program providing information, treatment follow-up, and support services for patients and families during treatment.

Products and services

  • Benzimir Hematology medication produced by Bioprofarma Bagó for the treatment of hematological conditions.
  • Anastradex Oncology medication for cancer treatment produced by Bioprofarma Bagó.
  • Actiluzol Special treatment medication containing riluzole for neurological conditions.
  • Hutus Urology medication containing enzalutamide for prostate cancer treatment.
  • Eibanta Treatment for acute attacks of hereditary angioedema, presented as a pre-filled syringe with 30mg icatibanto and 25G hypodermic needle.
  • Antixan Special treatment containing edaravone for neurological conditions.
  • Gaust Special treatment containing miglustat for rare diseases.
  • Kalisma Special treatment containing sulthiame.
  • Ragnerol Special treatment containing caspofungin for antifungal therapy.
  • Androstat Urology medication containing cyproterone acetate for prostate cancer treatment, presented as 50mg x 50 tablets.
  • Bidrostat Urology medication containing bicalutamide for prostate cancer.
  • CarciVac Urology medication containing Onco BCG (Bacillus Calmette-Guérin) for bladder cancer treatment.
  • Flutrax Urology medication containing flutamide for prostate cancer.
  • Kestava Urology medication containing abiraterone acetate for prostate cancer.
  • Mitotie Urology medication containing mitomycin for cancer treatment.
  • Paknira Urology medication containing apalutamide for prostate cancer.
  • Sinresor Urology medication containing zoledronic acid.
  • UroControl Urology diagnostic product for liquid biopsy in urine testing.
  • Urodif Dúo Urology medication combining dutasteride and tamsulosin hydrochloride.
  • PRIORIDAR Patient Program Patient support program providing information, treatment follow-up, and healthy lifestyle guidance for patients and families undergoing treatment with Bioprofarma Bagó medications.

Companies that use Bioprofarma Bagó

Customer profile

Segments5 records

Ideal customer profiles2 records

Bioprofarma Bagó technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Bioprofarma Bagó partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Mundo Animal (Brazil)coreStrategic or Co-development Partner · 1 January 2025Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) in January 2025 to expand into the pet care market in Brazil, complementing the Mayors acquisition and strengthening the group's Latin American pet health positioning.
  • Mayors (Argentina)coreStrategic or Co-development Partner · 1 January 2022Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) to expand into the pet care market in Argentina as part of the group's pet health strategy.
  • EriochemcoreStrategic or Co-development PartnerBioprofarma Bagó acquired 100% of Eriochem, an Argentine laboratory specializing in oncology medications based in Entre Rios. This acquisition enables synergies in research, production, and commercialization aligned with Bioprofarma Bago's high-impact therapeutic strategy, strengthening their oncology portfolio.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Bioprofarma Bagó competitors and assessment

Company assessment

Broad incumbents

  • Teva Pharmaceutical Industries: Global specialty and generics leader with strong LATAM and emerging market presence. Comparable as a large-scale competitor offering both specialty and generic versions of many molecules Bioprofarma distributes.
  • Laboratorios Bagó: Parent group of Bioprofarma Bagó and one of the largest Argentine pharmaceutical companies. Operates broadly across multiple therapeutic areas including animal health (Biogénesis Bagó); provides the corporate and distribution backbone for Bioprofarma's specialty division.
  • Astellas Pharma: Global originator of enzalutamide (Xtandi), directly competing with Bioprofarma's Hutus in prostate cancer. Representative of the multinational originator competition Bioprofarma faces in urology oncology.

Direct peers

  • Laboratorios Roemmers: Leading Argentine pharmaceutical company with a broad branded specialty and primary care portfolio across Latin America. Comparable as a fellow Argentine pharma with multi-country LATAM distribution and similar therapeutic breadth.
  • Eriochem: Argentine oncology-focused laboratory recently acquired by Bioprofarma Bagó. Specializes in oncology medications for high-complexity treatments, making it the closest direct comparator on therapeutic focus and geography.
  • Gador: Argentine pharmaceutical company with strong specialty and oncology presence across LATAM. Directly comparable therapeutic categories (oncology, specialty care) and similar regional distribution model.
  • Laboratorios Raffo: Argentine specialty pharmaceutical company with branded generics and specialty products across oncology and complex therapies. Comparable as a mid-sized Argentine pharma competing in similar therapeutic niches.
  • Elea Phoenix: Argentine pharmaceutical group (formed by merger of Elea and Phoenix) with branded specialty products across LATAM. Comparable in scale, therapeutic breadth, and Argentine-headquartered specialty pharma positioning.

Regional players

  • Laboratorio Chile (Teva affiliate): Major LATAM specialty/generics player with strong presence in Chile and broader Andean/Pacific Alliance markets where Bioprofarma also competes in oncology and specialty therapeutics.

Others

  • Biogénesis Bagó: Animal-health subsidiary of the same Bagó Group, with 200+ pet health SKUs and top-10 LATAM ranking. Sister company rather than direct competitor; included as ecosystem context for the parent group's broader pharmaceutical platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Bioprofarma Bagó social profiles

Digital presence

Bioprofarma Bagó financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioprofarma Bagó leadership team

Management profile

Number of profiles

Profiles1 record

Bioprofarma Bagó subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Bioprofarma Bagó funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioprofarma Bagó M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioprofarma Bagó

What does Bioprofarma Bagó do?

Bioprofarma Bagó develops, manufactures, and commercializes high-complexity prescription medications for the treatment of hematological, oncological, and urological conditions, special treatments, and rare diseases. The portfolio includes specialty drugs such as Benzimir (hematology), Anastradex (oncology), Hutus and Androstat (prostate cancer), and Eibanta (hereditary angioedema), distributed through healthcare institutions, hospitals, and pharmacies across Latin America, Asia, the Middle East, and Eastern Europe.

Is Bioprofarma Bagó a public or private company?

Bioprofarma Bagó is a private company. It is classified as corporate owned and is currently operating.

When was Bioprofarma Bagó founded?

Bioprofarma Bagó was founded in 2003. It employs 101 to 250 people.

Where is Bioprofarma Bagó based?

Bioprofarma Bagó is headquartered in Buenos Aires, Argentina, in the Latin America region.

How does Bioprofarma Bagó make money?

One revenue line is on record: prescription Pharmaceutical Products.

Who are Bioprofarma Bagó's main competitors?

Broad incumbents on record are Teva Pharmaceutical Industries, Laboratorios Bagó and Astellas Pharma. Direct peers are Laboratorios Roemmers, Eriochem, Gador, Laboratorios Raffo and Elea Phoenix. Laboratorio Chile (Teva affiliate) is listed as a regional player. Biogénesis Bagó is listed as an others.

Does Bioprofarma Bagó have an API?

No public API is recorded for Bioprofarma Bagó.

What industry is Bioprofarma Bagó in?

Bioprofarma Bagó's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals